Drugs / Rovadicitinib
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06388759 | Aug 2022 → Aug 2025 | myelofibrosis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04944043 | Jun 2021 → Jun 2023 overdue | chronic graft versus host disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06300320 | May 2024 → Oct 2025 overdue | chronic graft versus host disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06682169 | Nov 2024 → Oct 2029 expected | chronic graft versus host disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rovadicitinib | “Rovadicitinib (TQ05105) is a novel, oral dual Janus kinase 1/2 and rho-associated coiled-coil-containing protein kinase-1/2 inhibitor targeting inflammatory and fibrotic...” PMID 40009501 ↗ Jun 20253“Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.” NCT06300320 ↗ “Rovadicitinib (TQ05105) is a first-in-class, oral, small-molecule Janus kinase (JAK)/Rho-associated kinase (ROCK) inhibitor.” PMID 40752760 ↗ Aug 2025 |
| Known as | TQ05105 | “Rovadicitinib (TQ05105) is a novel, oral dual Janus kinase 1/2 and rho-associated coiled-coil-containing protein kinase-1/2 inhibitor targeting inflammatory and fibrotic...” PMID 40009501 ↗ Jun 20252“Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.” NCT06300320 ↗ “Rovadicitinib (TQ05105) is a first-in-class, oral, small-molecule Janus kinase (JAK)/Rho-associated kinase (ROCK) inhibitor.” PMID 40752760 ↗ Aug 2025 |
| Action | Inhibit | “TQ05105 tablet is a Janus Kinase (JAK) inhibitor, which can inhibit the abnormal activation of JAK 2-V617F mutation, thereby inhibiting the sustained abnormal activation of JAK...” NCT04944043 ↗ |
| Modality | Small molecule | “Rovadicitinib (TQ05105) is a first-in-class, oral, small-molecule Janus kinase (JAK)/Rho-associated kinase (ROCK) inhibitor.” PMID 40752760 ↗ Aug 2025 |
| Route | Oral | “TQ05105 tablet 10mg given orally” NCT04944043 ↗ |
| Target | ROCK2 | “It can inhibit the sustained abnormal activation of the Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway and also inhibit Rho associated...” NCT06682169 ↗ |